about
Analysis of protease-activated receptor-1 and -2 in human scar formation.Design, synthesis, biological activity, and ADME properties of pyrazolo[3,4-d]pyrimidines active in hypoxic human leukemia cells: a lead optimization study.Regulation of angiogenesis by Th1- and Th2-type cytokines.Role of inflammatory mediators in angiogenesis.Role of the hypoxic microenvironment in the antitumor activity of tyrosine kinase inhibitors.A ribonuclease protection assay-based approach for analysis of angiogenic gene expression in archival tissues.N-[2-Methyl-5-(triazol-1-yl)phenyl]pyrimidin-2-amine as a scaffold for the synthesis of inhibitors of Bcr-Abl.Interleukin-1β regulates the migratory potential of MDAMB231 breast cancer cells through the hypoxia-inducible factor-1α.Protease-activated receptor-1 (PAR-1) promotes the motility of human melanomas and is associated to their metastatic phenotype.Identification of a functional role for the protease-activated receptor-1 in hypoxic breast cancer cells.Structure-based optimization of pyrazolo[3,4-d]pyrimidines as Abl inhibitors and antiproliferative agents toward human leukemia cell lines.Protease-activated receptor 1-selective antagonist SCH79797 inhibits cell proliferation and induces apoptosis by a protease-activated receptor 1-independent mechanism.Inhibition of Bcr-Abl phosphorylation and induction of apoptosis by pyrazolo[3,4-d]pyrimidines in human leukemia cells.Pyrazolo[3,4-d]pyrimidines as potent antiproliferative and proapoptotic agents toward A431 and 8701-BC cells in culture via inhibition of c-Src phosphorylation.Inducible nitric oxide synthase activity correlates with lymphangiogenesis and vascular endothelial growth factor-C expression in head and neck squamous cell carcinoma.New pyrazolo[3,4-d]pyrimidines endowed with A431 antiproliferative activity and inhibitory properties of Src phosphorylation.Pyrazolo[3,4-d]pyrimidines endowed with antiproliferative activity on ductal infiltrating carcinoma cells.p66SHC promotes apoptosis and antagonizes mitogenic signaling in T cells.2-Hydroxypropyl-β-cyclodextrin strongly improves water solubility and anti-proliferative activity of pyrazolo[3,4-d]pyrimidines Src-Abl dual inhibitors.Plasma levels of immunosuppressive mediators during cardiopulmonary bypass.The Shc protein RAI promotes an adaptive cell survival program in hypoxic neuroblastoma cells.Protease-activated receptor-2 downregulation is associated to vitiligo lesions.Early response to bleomycin is characterized by different cytokine and cytokine receptor profiles in lungs.Short-term hypoxia enhances the migratory capability of dendritic cell through HIF-1α and PI3K/Akt pathway.Hypoxia affects dendritic cell survival: role of the hypoxia-inducible factor-1α and lipopolysaccharide.The lymphatic route. VIII. Distribution and plasma clearance of recombinant human interleukin-2 after SC administration with albumin in patientsThrombin Enhances T Cell Proliferative Responses and Cytokine ProductionStudies on tumor necrosis factor (TNF)—I. Pharmacokinetics of human recombinant TNF in rabbits and monkeys after intravenous administrationThe lymphatic route—II. Pharmacokinetics of human recombinant interferon-α2 injected with albumin as a retarder in rabbitsThe lymphatic route—III. Pharmacokinetics of human natural interferon-β injected with albumin as a retarder in rabbitsThe lymphatic route. 1) Albumin and hyaluronidase modify the normal distribution of interferon in lymph and plasmaIdentification of thrombin-like activity in ovarian cancer associated ascites and modulation of multiple cytokine networksThrombin Inhibits IFN-γ Production in Human Peripheral Blood Mononuclear Cells by Promoting a Th2 ProfileExpression of protease-activated receptors 1 and 2 in melanocytic nevi and malignant melanomaIn vitro cytokine production and T-cell proliferation in patients undergoing cardiopulmonary by-passHuman alpha-thrombin stimulates proliferation of interferon-gamma differentiated, growth-arrested U937 cells, overcoming differentiation-related changes in expression of p21CIP1/WAF1 and cyclin D1Interleukin 10 production in patients undergoing cardiopulmonary bypass: evidence of inhibition of Th-1-type responsesThrombin receptor expression and responsiveness of human monocytic cells to thrombin is linked to interferon-induced cellular differentiationThrombin regulates the expression of proangiogenic cytokines via proteolytic activation of protease-activated receptor-1Thrombin enhancement of interleukin-1 expression in mononuclear cells: involvement of proteinase-activated receptor-1
P50
Q33289128-7811BE39-B047-4ABA-B72E-D002B58F3E06Q33857013-8C428EC7-2143-48E2-A76E-DDA82A529E2CQ35061274-B5D45EEF-B06B-4B07-93E3-E5DF84FB384AQ36048112-C1CCB1D3-518D-41FB-80AC-489AE741014CQ37886235-B21A16B2-9E84-49A0-A6ED-B6B785D0DE8AQ38430664-ED3DE0E7-0865-41F9-9A06-F16FE2B9DC0BQ39459749-E2252E1F-2B3F-4D4C-A405-5919533F73AEQ39662317-3515E143-5EDD-41F5-9F97-E5B659F00ADAQ39750500-19418D56-85B1-481A-8B5E-B6A0BBB1B4A5Q39910521-D2E28E5F-BAC2-40EF-A083-7B2EC066D106Q40015558-630A26EB-2994-469C-8E52-13A93F37D082Q40118103-E4B63710-FB1B-4390-AEC2-F37CA0C7FA88Q40171974-3E65FFF1-6C2E-4D99-BF22-96904DA6E177Q40310123-C51C55F3-B0AC-4224-92B7-2C83386B3C03Q40352864-585F9B8D-45D8-4409-8FFC-7047FB2C2B79Q40562784-C60E3B1A-98D6-4BF2-98A7-E6ABD3E2C3A7Q40577395-3B4B5105-5B46-433A-B7FF-4B8A02E136A5Q40583604-688FB406-71C0-4AF6-9D90-E8E3AC7BCF3FQ42849777-0EB9CEEA-E31F-4F78-8832-C4BA9186F5E4Q43204333-0CDDD580-082F-445C-B92B-8EF49C3B375FQ47618719-C092D86F-DFF6-413B-A4D2-B2866F4F5B03Q48004573-4E62A9DE-5F50-4CEB-AEE3-423669B4E5F3Q48853636-24BF873A-CA79-4A2D-AB3F-2F5E36DAE808Q50663332-FE6D2994-D345-472C-9B05-F2E230F53861Q53257878-FDF390D4-3FA7-496D-9DA1-837E023E0C42Q59189574-3D3F6D36-39D5-4E06-8179-F1958F29CB66Q59189579-AD4684E8-100C-40CB-A3F1-479EA8D56FCBQ59189611-AACE318C-BDE9-48FE-82A8-76BAB9B379E0Q59189629-07C5882C-981D-410C-BB6F-CDE441CC65DBQ59189632-AFAF9FE2-8E29-4E68-A9C6-3A83B3532414Q59189637-D658DFD5-BF24-41FD-8DF2-6241AC08ACE1Q60043700-7FDACFCE-887D-45E5-89E5-7AC816A6F7F8Q60695415-996290CE-2A71-4EFB-96AD-FFD60A204A80Q60695417-64E77CB8-6509-4C17-9DAE-EBD42BE25250Q72309958-9DCD7ADB-5696-4E54-AEA5-3A768D3831B8Q74102972-DAFAC06C-DA21-4E13-A1A2-D21AF1D6320AQ74612328-67ADAA8D-610D-4046-BE0B-9B9629ABFA54Q77221259-1DBBC884-AF30-42C0-AA99-B22B8121AA1CQ77753214-AA8D5812-0563-45B1-8791-1206A80DF16DQ78844910-23641820-8672-4E51-AFDF-1C879D37BE6D
P50
description
onderzoeker
@nl
researcher ORCID ID = 0000-0002-9600-2486
@en
name
Antonella Naldini
@ast
Antonella Naldini
@en
Antonella Naldini
@es
Antonella Naldini
@nl
type
label
Antonella Naldini
@ast
Antonella Naldini
@en
Antonella Naldini
@es
Antonella Naldini
@nl
altLabel
antonella naldini
@en
prefLabel
Antonella Naldini
@ast
Antonella Naldini
@en
Antonella Naldini
@es
Antonella Naldini
@nl
P1053
O-6522-2015
P106
P1153
7004148239
P21
P31
P496
0000-0002-9600-2486